High Doses of ANA12 Improve Phenobarbital Efficacy in a Model of Neonatal Post-Ischemic Seizures

Area of Science:

• Neuroscience
• Pharmacology
• Neonatal Medicine

Background:

• Phenobarbital (PB) is a first-line treatment for neonatal seizures.
• Many neonatal seizures, especially those from perinatal ischemia, are resistant to PB.
• The TrkB antagonist ANA12 showed promise in previous studies for enhancing PB efficacy.

Purpose of the Study:

• To evaluate higher doses of ANA12 (10 and 20 mg/kg) in combination with PB.
• To assess the impact of ANA12 on seizure burden, neuronal cell death, and neurodevelopment.
• To determine the safety and effectiveness of ANA12 as an adjunctive treatment for pharmacoresistant neonatal seizures.

Main Methods:

• Utilized a unilateral carotid ligation model in P7 mouse pups to induce ischemic stroke.
• Administered single doses of ANA12 (10 or 20 mg/kg) 1 hour after ligation.
• Assessed seizure burden, cell death (Fluoro-Jade staining), and neurodevelopmental reflexes (righting reflex, negative geotaxis, open field test).

Main Results:

• ANA12 (10 and 20 mg/kg) significantly reduced seizure burden in P7 pups.
• Higher doses of ANA12 ameliorated neocortical and striatal neuron death.
• No impairment of developmental reflexes was observed with ANA12 treatment.

Conclusions:

• ANA12, at doses of 10-20 mg/kg, effectively enhances PB efficacy for perinatal ischemia-related seizures.
• ANA12 demonstrates potential as a safe and effective adjunctive therapy for pharmacoresistant neonatal seizures.
• Further clinical investigation of ANA12 is warranted for neonatal seizure treatment.